316 related articles for article (PubMed ID: 25249766)
1. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.
Inic Z; Zegarac M; Inic M; Markovic I; Kozomara Z; Djurisic I; Inic I; Pupic G; Jancic S
Clin Med Insights Oncol; 2014; 8():107-11. PubMed ID: 25249766
[TBL] [Abstract][Full Text] [Related]
2. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
3. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological classification and individualized treatment of breast cancer.
Hu H; Liu YH; Xu L; Zhao JX; Duan XN; Ye JM; Li T; Zhang H; Zhang S; Xiong Y
Chin Med J (Engl); 2013 Oct; 126(20):3921-5. PubMed ID: 24157157
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
6. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
Falck AK; Fernö M; Bendahl PO; Rydén L
BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
9. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients.
Kondov B; Milenkovikj Z; Kondov G; Petrushevska G; Basheska N; Bogdanovska-Todorovska M; Tolevska N; Ivkovski L
Open Access Maced J Med Sci; 2018 Jun; 6(6):961-967. PubMed ID: 29983785
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
11. Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013.
Ahn HJ; Jung SJ; Kim TH; Oh MK; Yoon HK
J Breast Cancer; 2015 Jun; 18(2):149-59. PubMed ID: 26155291
[TBL] [Abstract][Full Text] [Related]
12. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.
Maisonneuve P; Disalvatore D; Rotmensz N; Curigliano G; Colleoni M; Dellapasqua S; Pruneri G; Mastropasqua MG; Luini A; Bassi F; Pagani G; Viale G; Goldhirsch A
Breast Cancer Res; 2014 Jun; 16(3):R65. PubMed ID: 24951027
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtypes of invasive breast carcinoma of no special type, their correlation with histopathological features, Ki 67 index and tumor budding: A retrospective comparative study.
Radhakrishnan N; Mathews A; Rajeev KR; Nair PS; Bhargavan R; Viswanathan AJ
Indian J Pathol Microbiol; 2022; 65(4):772-780. PubMed ID: 36308179
[TBL] [Abstract][Full Text] [Related]
14. Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer.
Husni Cangara M; Miskad UA; Masadah R; Nelwan BJ; Wahid S
Breast Dis; 2021; 40(S1):S27-S31. PubMed ID: 34057115
[TBL] [Abstract][Full Text] [Related]
15. Preoperative MRI Evaluation of Axillary Lymph Nodes in Invasive Ductal Carcinoma: Comparison of Luminal A Versus Luminal B Subtypes in a Paradigm Using Ki-67 and Receptor Status.
Plaza MJ; Handa P; Esserman LE
AJR Am J Roentgenol; 2017 Apr; 208(4):910-915. PubMed ID: 28140614
[TBL] [Abstract][Full Text] [Related]
16. BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer.
Eom YH; Kim HS; Lee A; Song BJ; Chae BJ
J Breast Cancer; 2016 Sep; 19(3):252-260. PubMed ID: 27721874
[TBL] [Abstract][Full Text] [Related]
17. Association between molecular subtypes and lymph node status in invasive breast cancer.
Si C; Jin Y; Wang H; Zou Q
Int J Clin Exp Pathol; 2014; 7(10):6800-6. PubMed ID: 25400761
[TBL] [Abstract][Full Text] [Related]
18. Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype.
Yanagawa M; Ikemot K; Kawauchi S; Furuya T; Yamamoto S; Oka M; Oga A; Nagashima Y; Sasaki K
BMC Res Notes; 2012 Jul; 5():376. PubMed ID: 22830453
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
20. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
